https://scholars.lib.ntu.edu.tw/handle/123456789/189607
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 內科 | en |
dc.contributor.author | WEN, MING-SHIEN | en |
dc.contributor.author | LEE, MING-TA MICHAEL | en |
dc.contributor.author | CHEN, JIN-JER | en |
dc.contributor.author | CHUANG, HUI-PING | en |
dc.contributor.author | LU, LIANG-SUEI | en |
dc.contributor.author | CHEN, CHIEN-HSIUN | en |
dc.contributor.author | LEE, TSONG-HAI | en |
dc.contributor.author | KUO, CHI-TAI | en |
dc.contributor.author | KUAN, PEI-LIANG | en |
dc.contributor.author | CHEN, YING-FU | en |
dc.contributor.author | WU, JER-YUARN | en |
dc.contributor.author | CHEN, YUAN-TSONG | en |
dc.creator | 溫明賢;李明達;陳錦澤;莊惠評;呂良穗;陳建勳;李宗海;郭啟泰;管培良;陳英富;鄔哲源;陳垣崇 | zh-tw |
dc.creator | WEN, MING-SHIEN;LEE, MING-TA MICHAEL;CHEN, JIN-JER;CHUANG, HUI-PING;LU, LIANG-SUEI;CHEN, CHIEN-HSIUN;LEE, TSONG-HAI;KUO, CHI-TAI;KUAN, PEI-LIANG;CHEN, YING-FU;WU, JER-YUARN;CHEN, YUAN-TSONG | en |
dc.date | 2008 | en |
dc.date.accessioned | 2009-12-18T02:17:35Z | - |
dc.date.accessioned | 2018-07-11T06:17:03Z | - |
dc.date.available | 2009-12-18T02:17:35Z | - |
dc.date.available | 2018-07-11T06:17:03Z | - |
dc.date.issued | 2008 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/174612 | - |
dc.description.abstract | Polymorphisms in CYP 2C9 and VKOR C1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose . We conducted a prospective study in which warfarin dose was prescribed based on CYP 2C9 and VKOR C1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR ) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR >4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients’maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R2 of 0.62). This study demonstrated that pharmacogenetics- based dosing could improve time to stable, therapeutic INR , reduce adverse events, and achieve high sensitivity. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | CLINICAL PHARMACOLOGY & THERAPEUTICS v.84 n.1 pp.83-89 | en |
dc.relation.ispartof | Clinical Pharmacology & Therapeutics | en_US |
dc.title | Prospective Study of Warfarin Dosage Requirements Based on Cyp2c9 and Vkorc1 Genotypes | en |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/sj.clpt.6100453 | - |
dc.relation.pages | 83-89 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en_US | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。